CBR1

NADPH-dependent reductase with broad substrate specificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. Catalyzes the reduction of the antitumor anthracyclines doxorubicin and daunorubicin to the cardiotoxic compounds doxorubicinol and daunorubicinol (PubMed:15799708, PubMed:17344335, PubMed:17912391, PubMed:18449627, PubMed:18826943, PubMed:1921984, PubMed:7005231). Can convert prostaglandin E to prostaglandin F2-alpha (By similarity). Can bind glutathione, which explains its higher affinity for glutathione-conjugated substrates. Catalyzes the reduction of S-nitrosoglutathione (PubMed:17344335, PubMed:18826943). In addition, participates in the glucocorticoid metabolism by catalyzing the NADPH-dependent cortisol/corticosterone into 20beta-dihydrocortisol (20b-DHF) or 20beta-corticosterone (20b-DHB), which are weak agonists of NR3C1 and NR3C2 in adipose tissue (PubMed:28878267).

Belongs to the short-chain dehydrogenases/reductases (SDR) family.

Expressed in kidney (at protein level).

• Cytoplasm

CBR, CRN, SDR21C1, CBR1, Carbonyl reductase [NADPH] 1, 15-hydroxyprostaglandin dehydrogenase [NADP(+)], 20-beta-hydroxysteroid dehydrogenase, Alcohol dehydrogenase [NAD(P)+] CBR1, NADPH-dependent carbonyl reductase 1, Prostaglandin 9-ketoreductase, Prostaglandin-E(2) 9-reductase, Short chain dehydrogenase/reductase family 21C member 1, PG-9-KR

• entrezGene:873
• omim:114830
• swissprot:P16152

Proteins

30375Da